Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2804 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study
Yao-Fan Fang, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan
Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide population study.Background/Purpose: Autoimmune inflammatory diseases influence on pregnancy outcomes. But rare studies have focus on the…
Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Jakub Zavada¹, Lenka Szczukova², Karel Pavelka³ and Jiri Vencovsky³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…
Abstract Number: 1532 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year
John D. Reveille¹, Atul A. Deodhar², Diane D. Harrison³, Lilianne Kim³, Kim Hung Lo³ and Elizabeth C. Hsia⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…
Abstract Number: 1938 • 2017 ACR/ARHP Annual Meeting
TGFB1 Governs Osteoblast Differentiation in Ankylosing Spondylitis Via Modulating BMP2
Sungsin Jo¹, Seung Hyun Choi², Il-Hoon Sung³, Ye-Soo Park⁴ and Tae-Hwan Kim¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Choate Rosemary Hall, Wallingford, CT, ³Orthopaedic, Hanyang University Seoul Hospital, Seoul, Korea, Republic of (South), ⁴Orthopaedic, Hanyang University Guri Hospital, Guri, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis (AS) is characterized by inflammation, high osteoblastic activity, leading to ankyloses. Transforming growth factor beta 1 (TGFB1) has been known to be…
Abstract Number: 2880 • 2017 ACR/ARHP Annual Meeting
Clinical Evolution of Patients with Inflammatory Back Pain: A Population-Based Longitudinal Cohort Study
Runsheng Wang¹, Cynthia S. Crowson², Kerry Wright³ and Michael Ward⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴NIH/NIAMS, Bethesda, MD
Title: Clinical Evolution of Patients with Inflammatory Back Pain: a Population-Based Longitudinal Cohort Study Authors: Runsheng Wang1, Cynthia Crowson2, Kerry Wright2, Michael Ward31. Columbia University…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 1739 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
Walter P Maksymowych¹, Vibeke Strand², Peter Nash³, Howard Thom⁴, Andreas Karabis⁵, Kunal Gandhi⁶, Brian Porter⁶ and Steffen Jugl⁷, ¹University of Alberta, Edmonton, AL, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁴University of Bristol, Bristol, United Kingdom, ⁵MAPI Group, Houten, Netherlands, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of patients with active AS. However, there are no head-to-head randomized controlled trials (RCTs)…
Abstract Number: 2755 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients
Ahmed Omar¹, Laura Passalent², Renise Ayearst³, Ismail Sari¹, Anthony V. Perruccio⁴, Rajiv Gandhi⁵, Nigil Haroon¹ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Medicine, University Health Network, Toronto, ON, Canada, ⁴Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Department of Surgery - Orthopedics, Toronto Western Hospital, Assistant Professor, Department of Surgery, University of Toronto, Toronto, ON, Canada
Background/Purpose: Data on disease characteristics of geriatric patients (>=65 years) with AS are lacking. The objective of this study is to compare: 1) the clinical…
Abstract Number: 695 • 2016 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Xenofon Baraliakos¹, Michael Schiff², Karel Pavelka³, Ruvie Martin⁴, Brian Porter⁴ and Corine Gaillez⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of Colorado, School of Medicine, Denver, CO, ³Institute and Cliníc of Rheumatology, Charles University, Prague, Czech Republic, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The assessment of achieving, maintaining, and improving clinical response to biologics in Ankylosing Spondylitis (AS) is part of treat-to-target recommendations aimed at optimizing treatment…
Abstract Number: 1044 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Désirée van der Heijde², Xenofon Baraliakos³, Atul A. Deodhar⁴, Matt Brown⁵, Sarah Sherlock⁶, David Li⁷, Dona Fleishaker⁸ and Thijs Hendrikx⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor. Minimum clinically important differences (MCID) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI SI joint and spine…
Abstract Number: 1916 • 2016 ACR/ARHP Annual Meeting
Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Diahann Jansen¹, Elizabeth Klinken¹, Hendrik Nel², Soi Cheng Law², Helen Benham^3,4,5, Lisa Cummins⁶, Matthew Brown⁷, Tony Kenna², Ligong Liu⁸, David Fairlie⁸, Jamie Rossjohn^9,10,11, Mark Morrison³, Ranjeny Thomas³, Paraic O Cuiv¹, James McCluskey¹² and Alexandra Corbett¹², ¹The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Australia, ⁴University of Queensland School of Medicine, Brisbane, Australia, ⁵Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Woolloongabba, Australia, ⁷Queensland University of Technology, Brisbane, Australia, ⁸Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, ⁹Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ¹⁰Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ¹¹Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, ¹²Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia
Background/Purpose: Mucosal associated invariant T (MAIT) cells are an innate-like lymphocyte population predominant at mucosal sites, which express a semi-invariant T cell receptor restricted to…
Abstract Number: 2756 • 2016 ACR/ARHP Annual Meeting
Gender Differences in Body Composition with Dual-Energy X-Ray Absorptiometry in TNF-α Blocker Naive Ankylosing Spondylitis Patients
Sebastián Ibáñez^1,2, Ingrid M. Visman³, Christiaan van Denderen³, Willem F. Lems^4,5, M. Nurmohamed^4,6 and Irene van der Horst - Bruinsma⁴, ¹Reumatología, Clínica Alemana de Santiago, Santiago, Chile, ²Reumatología, Hospital Padre Hurtado, Santiago, Chile, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, New Caledonia, ⁶Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands
Background/Purpose: Data on body composition (BC) in Ankylosing Spondylitis (AS) are sparse and controversial. Female AS patients have less response to TNF-α blockers and a…
Abstract Number: 696 • 2016 ACR/ARHP Annual Meeting
Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab
S.C. Heslinga^1,2, M. T. Nurmohamed^1,3, A. H. Gerards⁴, E. Griep⁵, C. Koehorst⁶, M. R. Kok⁷, A. Schilder⁸, M. Verhoef⁹ and I.E. Van der Horst - Bruinsma^1,2, ¹Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Antonius Hospital, Sneek, Netherlands, ⁶Rheumatology, Gelre Hospital, Apeldoorn, Netherlands, ⁷Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁸Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁹Immunology, MSD the Netherlands, Haarlem, Netherlands
Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective…
Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].